International Journal of Radiation Oncology * Biology * Physics
Volume 61, Issue 4 , Pages 1117-1122 , 15 March 2005

A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non–small-cell lung cancer (NSCLC)

This study was presented in part at the 38th Annual Meeting of ASCO in Orlando, Florida, May 18–21, 2002.

  • Satoshi Ishikura, M.D.

      Affiliations

    • Division of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • Corresponding Author InformationReprint requests to: Satoshi Ishikura, M.D., Radiation Oncology Division, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan. Tel: (+81) 4-7133-1111; Fax: (+81) 4-7131-4724
    • ,
  • Yuichiro Ohe, M.D.

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Keiji Nihei, M.D.

      Affiliations

    • Division of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Kaoru Kubota, M.D.

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Ryutaro Kakinuma, M.D.

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Hironobu Ohmatsu, M.D.

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Koichi Goto, M.D.

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Seiji Niho, M.D.

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Yutaka Nishiwaki, M.D.

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Takashi Ogino, M.D.

      Affiliations

    • Division of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

Received 29 March 2004 ,Revised 9 July 2004 ,Accepted 13 July 2004.

References 

  1. The editorial board of the cancer statistics in Japan (ed). Cancer statistics in Japan 2003. Foundation for promotion of cancer research. http://www.ncc.go.jp/en/statistics/2003/data03.pdf.
  2. Dillman RO , Herndon J , Seagren SL , et al.  Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial . J Natl Cancer Inst . 1996;88:1210–1215
  3. Non-small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials . Br Med J . 1995;311:899–909
  4. Schaake-Koning C , van den Bogaert W , Dalesio O , et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer . N Engl J Med . 1992;326:524–530
  5. Sause WT , Scott C , Taylor S , et al.  88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer . Radiation Therapy Oncology Group (RTOG) J Natl Cancer Inst . 1995;87:198–205
  6. Sause W , Kolesar P , Taylor S , et al.  Final results of phase III trial in regionally advanced unresectable non-small-cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group . Chest . 2000;117:358–364
  7. Furuse K , Fukuoka M , Kawahara M , et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer . J Clin Oncol . 1999;17:2692–2699
  8. Curran W, Scott C, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 94–10 [Abstract]. Proc Am Soc Clin Oncol 2003;22:621a.
  9. Saunders M , Dische S , Barrett A , et al.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial . Radiother Oncol . 1999;52:137–148
  10. Mehta MP , Tannehill SP , Adak S , et al.  Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: Results of Eastern Cooperative Oncology Group 4593 . J Clin Oncol . 1998;16:3518–3523
  11. Kaplan EL , Meier P . Nonparametric estimation from incomplete observations . J Am Stat Assoc . 1958;53:457–481
  12. Byhardt RW , Scott CB , Ettinger DS , et al.  Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer (Results of Radiation Therapy Oncology Group 90–15) . Cancer . 1995;75:2337–2344
  13. Zemanova M, Petruzelka L, Zemanova M. Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomized phase II study [Abstract]. Proc Am Soc Clin Oncol 2002;21:290a.
  14. Macbeth F . An uncharted country . Clin Oncol (R Coll Radiol) . 1999;11:71–72
  15. Saunders MI . Programming of radiotherapy in the treatment of non-small-cell lung cancer—a way to advance care . Lancet Oncol . 2001;2:401–408
  16. Saunders MI , Rojas A , Lyn BE , et al.  Dose-escalation with CHARTWEL (Continuous Hyperfractionated Accelerated Radiotherapy Week-End Less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer . Clin Oncol . 2002;14:352–360
  17. Bentzen SM , Saunders MI , Dische S . From CHART to CHARTWEL in non-small cell lung cancer: Clinical radiobiological modelling of the expected change in outcome . Clin Oncol . 2002;14:372–381
  18. Baumann M , Herrmann T , Matthiessen W , et al.  CHARTWEL-Bronchus (ARO 97–1): A randomized multicenter trial to compare conventional fractionated radiotherapy with CHARTWEL radiotherapy in inoperable non-small-cell bronchial carcinoma . Strahlenther Onkol . 1997;173:663–667
  19. Belani CP, Wang W, Johnson DH, et al. Induction chemotherapy followed by standard thoracic radiotherapy (Std. TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage IIIA & B non-small cell lung cancer (NSCLC): Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597) [Abstract]. Proc Am Soc Clin Oncol 2003;22:622a.
  20. Kelly K , Crowley J , Bunn PA , et al.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group Trial . J Clin Oncol . 2001;19:3210–3218
  21. Pfister DG , Johnson DH , Azzoli CG , et al.  American Society of Clinical Oncology treatment of unresectable non–small-cell lung cancer guideline: Update 2003 . J Clin Oncol . 2004;22:330–353
  22. Graham MV, Winter K, Purdy JA, et al. Preliminary results of a Radiation Therapy Oncology Group trial (RTOG 9311), a dose escalation study using 3D conformal radiation therapy in patients with inoperable nonsmall cell lung cancer [Abstract]. Int J Radiat Oncol Biol Phys 2001;51:20S.
  23. Rosenzweig KE , Sim SE , Mychalczak B , et al.  Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy . Int J Radiat Oncol Biol Phys . 2001;50:681–685
  24. Hayman JA , Martel MK , Ten Haken RK , et al.  Dose escalation in non–small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial . J Clin Oncol . 2001;19:127–136
  25. Thirion P, Mc Gibney C, Holmberg O, et al. 3-dimensional conformal radiation therapy (3DCRT) permits radiobiological dose escalation for non-small-cell lung cancer (NSCLC): Preliminary results of a phase I/II trial [Abstract]. Proc Am Soc Clin Oncol 2001;20:344a.
  26. Gandara DR , Chansky K , Albain KS , et al.  Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504 . J Clin Oncol . 2003;21:2004–2010
  27. Milas L , Fan Z , Andratschke NH , et al.  Epidermal growth factor receptor and tumor response to radiation: In vivo preclinical studies . Int J Radiat Oncol Biol Phys . 2004;58:966–971
  28. Ochs JS . Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors . Int J Radiat Oncol Biol Phys . 2004;58:941–949
  29. Choy H , Milas L . Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance? . J Natl Cancer Inst . 2003;95:1440–1452

PII: S0360-3016(04)02086-3

doi: 10.1016/j.ijrobp.2004.07.692

International Journal of Radiation Oncology * Biology * Physics
Volume 61, Issue 4 , Pages 1117-1122 , 15 March 2005

Article Tools

* Image Usage & Resolution